GLABF.US Gemina Laboratories Ltd
- Market cap
- USD 3.83M
- P/E
- -
- P/B
- 44.10x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jan 2026.
Is GLABF.US undervalued?
Graham numberThe Graham number of Gemina Laboratories Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Gemina Laboratories Ltd fundamental analysis
No fundamental analysis for Gemina Laboratories Ltd yet.
Gemina Laboratories Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Gemina Laboratories Ltd
Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company's products include LEGIO X COVID-19, a COVID-19 rapid antigen test; and LEGIO X Influenza AB, an influenza AB multiplex lateral flow test. It also develops respiratory syncytial virus and tuberculosis. Gemina Laboratories Ltd. was incorporated in 2017 and is headquartered in Burnaby, Canada.
Full company profileGemina Laboratories Ltd financial statements
Gemina Laboratories Ltd annual financial statements
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | - | 0.00 | -5.44K | 0.00 | 0.00 | 21.5K |
| Gross Profit | -12.1K | -43.8K | -50.3K | -93.4K | -113K | -16.0K |
| Operating Income | -646K | -4.73M | -5.98M | -5.09M | -3.91M | -2.24M |
| EBITDA | -634K | -4.69M | -5.93M | -5.10M | -3.80M | -2.20M |
| Net Income | -834K | -4.73M | -5.98M | -5.22M | -4.07M | -2.34M |
| EPS | -0.02 | -0.10 | -0.10 | -0.07 | -0.06 | -0.03 |
| Balance Sheet | ||||||
| Total Assets | 2.53M | 1.42M | 1.87M | 1.46M | 1.44M | 1.62M |
| Total Liabilities | 2.37M | 476K | 1.95M | 3.04M | 5.87M | 7.60M |
| Shareholders' Equity | 160K | 944K | -71.8K | -1.59M | -4.44M | -5.98M |
| Cash & Short-term Investments | 898K | 1.16M | 83.1K | 990.00 | 703.00 | 482K |
| Total Debt | 98.1K | 46.1K | 241K | 485K | 1.27M | 1.30M |
| Cash Flow | ||||||
| Operating Cash Flow | -319K | -3.87M | -4.51M | -3.24M | -1.30M | -519K |
| Capital Expenditure | 9.80K | 9.80K | 79.6K | 41.4K | 0.00 | 4.09 |
| Free Cash Flow | -319K | -3.88M | -4.59M | -3.29M | -1.30M | -519K |
| Ratios | ||||||
| ROE | -521.5% | -501.5% | - | - | - | - |
| ROA | -33.0% | -333.4% | -318.9% | -358.2% | -283.2% | -144.4% |
| Net Profit Margin | - | - | - | - | - | -10,893.2% |
| Debt to Equity | 0.61x | 0.05x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Gemina Laboratories Ltd dividends
Gemina Laboratories Ltd has not paid dividends in the last 6 fiscal years.
Who owns Gemina Laboratories Ltd
- Insiders 44.72%
- Institutions 0.00%
- Public & others 55.28%
- Shares outstanding 76.6M
- Free float 43.7M
Gemina Laboratories Ltd company profile
- Company name
- Gemina Laboratories Ltd
- Ticker
- GLABF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- January
- Address
- 3600 Gilmore Way, Burnaby, BC, Canada, V5G 4W8
- Phone
- 604-760-1997
- Website
- geminalabs.com
About Gemina Laboratories Ltd
Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company's products include LEGIO X COVID-19, a COVID-19 rapid antigen test; and LEGIO X Influenza AB, an influenza AB multiplex lateral flow test. It also develops respiratory syncytial virus and tuberculosis. Gemina Laboratories Ltd. was incorporated in 2017 and is headquartered in Burnaby, Canada.
Gemina Laboratories Ltd management
3- Dr. Robert Crandall GreeneCEO & Director
- John F. PrinsChief Financial Officer
- Dr. Christine Buerki Ph.D.Head of Research & Development